HBV/HCV co-infection

Epidemiology & Risks - The Double Trouble

• Shared Transmission: Primarily via parenteral routes.
  • Intravenous drug use (IVDU) is the leading risk factor.
  • Other risks: high-risk sexual contact, vertical transmission, unsafe medical procedures.
• Accelerated Disease: Co-infection significantly ↑ risk and speed of progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC) compared to monoinfection.

⭐ In many co-infected individuals, HBV is dominant, leading to suppressed HCV replication (low HCV RNA). HCV can flare after HBV treatment.

Pathophysiology - Viral Tug-of-War

• Viral Interference: HBV & HCV are hepatotropic viruses that compete for host resources, leading to a pattern of viral dominance where one virus actively suppresses the replication of the other.
• Common Scenario: HCV usually dominates, leading to:
  • ↓ HBV DNA levels (often to undetectable levels).
  • A state of "occult HBV infection" (HBsAg-negative, but anti-HBc positive).
• Clinical Significance: The viral balance is dynamic. The suppressed virus can reactivate if the dominant one is cleared, e.g., during antiviral therapy.

⭐ Reactivation of HBV upon treatment of HCV with direct-acting antivirals (DAAs) is a major clinical concern, potentially causing fulminant hepatitis. Always screen for HBV (HBsAg, anti-HBs, anti-HBc) before initiating HCV therapy.

Diagnosis & Serology - The Viral Fingerprints

• Initial Dual Screening: Simultaneously test for HBsAg and anti-HCV antibodies in all at-risk patients.
• Confirmation with NAT: Positive screens require Nucleic Acid Testing (NAT) for active infection confirmation.
  • HBV DNA (quantitative)
  • HCV RNA (quantitative)
• HBV Panel: A full HBV panel (HBsAg, anti-HBs, anti-HBc) is crucial to determine immune status or chronic infection stage.

• Occult HBV Infection (OBI): Common scenario where HBsAg is negative, but anti-HBc is positive. Detectable low-level HBV DNA confirms OBI.

⭐ High-Yield: HCV is the dominant virus; it often suppresses HBV replication. Treating HCV with Direct-Acting Antivirals (DAAs) can lead to a dangerous flare of previously latent HBV.

Treatment Algorithms - The Suppression Strategy

• Primary Goal: Achieve HCV Sustained Virologic Response (SVR) while preventing HBV reactivation.
• Core Principle: Initiate HCV treatment with Direct-Acting Antivirals (DAAs) first.
• Mandatory Monitoring: All patients must be monitored for HBV reactivation before and during HCV therapy.

⭐ FDA Black Box Warning: Treating HCV with DAAs carries a risk of HBV reactivation in co-infected patients. This can lead to fulminant hepatitis, hepatic failure, or death. Screen all patients for HBV before starting DAAs.

Complications & Prognosis - The Long Game

• Accelerated Fibrosis: Faster progression to cirrhosis, decompensated liver disease (ascites, encephalopathy), and hepatocellular carcinoma (HCC) compared to mono-infection.
• ↑ Mortality: Significantly higher risk of liver-related death.
• Viral Interaction: HCV is often dominant, leading to suppression of HBV replication (↓ HBV DNA).

⭐ Reactivation Risk: Treating HCV with Direct-Acting Antivirals (DAAs) can cause a flare of HBV replication, potentially leading to fulminant hepatitis. Screen for HBV before starting HCV therapy.

High‑Yield Points - ⚡ Biggest Takeaways

• Co-infection with HBV and HCV dramatically accelerates progression to severe liver disease, including cirrhosis and hepatocellular carcinoma (HCC).
• Viral interference is common, with HCV often suppressing HBV replication, leading to low or undetectable HBV DNA.
• Crucially, screen for HBV (HBsAg, anti-HBc) before starting HCV direct-acting antivirals (DAAs) to prevent HBV reactivation.
• HBV reactivation during or after DAA therapy can cause fulminant hepatitis.
• Management is complex, often requiring dual therapy and specialist consultation.